{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:12:19Z","timestamp":1778206339004,"version":"3.51.4"},"reference-count":133,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Yellow fever is a potentially fatal, mosquito-borne viral disease that appears to be experiencing a resurgence in endemic areas in Africa and South America and spreading to non-endemic areas despite an effective vaccine. This trend has increased the level of concern about the disease and the potential for importation to areas in Asia with ecological conditions that can sustain yellow fever virus transmission. In this article, we provide a broad overview of yellow fever burden of disease, natural history, treatment, vaccine, prevention and control initiatives, and vaccine and therapeutic agent development efforts.<\/jats:p>","DOI":"10.3390\/vaccines7040179","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T11:30:19Z","timestamp":1573212619000},"page":"179","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7741-7072","authenticated-orcid":false,"given":"Kay M.","family":"Tomashek","sequence":"first","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Bethesda, MD 20892-9826, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Challberg","sequence":"additional","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Bethesda, MD 20892-9826, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema U.","family":"Nayak","sequence":"additional","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Bethesda, MD 20892-9826, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen F.","family":"Schiltz","sequence":"additional","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Bethesda, MD 20892-9826, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.coviro.2019.01.001","article-title":"Emergence and re-emergence of mosquito-borne arboviruses","volume":"34","author":"Huang","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hamlet, A., Jean, K., Perea, W., Yactayo, S., Biey, J., Van Kerkhove, M., Ferguson, N., and Garske, T. (2018). The seasonal influence of climate and environment on yellow fever transmission across Africa. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006284"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Weetman, D., Kamgang, B., Badolo, A., Moyes, C.L., Shearer, F.M., Coulibaly, M., Pinto, J., Lambrechts, L., and McCall, P.J. (2018). Aedes Mosquitoes and Aedes-Borne Arboviruses in Africa: Current and Future Threats. Int. J. Environ. Res. Public Health, 15.","DOI":"10.3390\/ijerph15020220"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hamrick, P.N., Aldighieri, S., Machado, G., Leonel, D.G., Vilca, L.M., Uriona, S., and Schneider, M.C. (2017). Geographic patterns and environmental factors associated with human yellow fever presence in the Americas. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005897"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/22221751.2019.1568180","article-title":"Haemagogus leucocelaenus and Haemagogus janthinomys are the primary vectors in the major yellow fever outbreak in Brazil, 2016\u20132018","volume":"8","author":"Abreu","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1126\/science.aau8225","article-title":"The reemergence of yellow fever","volume":"361","author":"Barrett","year":"2018","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/j.ijid.2012.03.004","article-title":"Epidemiological and laboratory characterization of a yellow fever outbreak in northern Uganda, October 2010\u2013January 2011","volume":"16","author":"Wamala","year":"2012","journal-title":"Int. J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kwagonza, L., Masiira, B., Kyobe-Bosa, H., Kadobera, D., Atuheire, E.B., Lubwama, B., Kagirita, A., Katushabe, E., Kayiwa, J.T., and Lutwama, J.J. (2018). Outbreak of yellow fever in central and southwestern Uganda, February-may 2016. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3440-y"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lilay, A., Asamene, N., Bekele, A., Mengesha, M., Wendabeku, M., Tareke, I., Girmay, A., Wuletaw, Y., Adossa, A., and Ba, Y. (2017). Reemergence of yellow fever in Ethiopia after 50 years, 2013: Epidemiological and entomological investigations. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2435-4"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3201\/eid2210.160818","article-title":"Resurgence of Yellow Fever in Angola, 2015\u20132016","volume":"22","author":"Grobbelaar","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(16)30513-8","article-title":"Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015\u201316: A modelling study","volume":"17","author":"Kraemer","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","unstructured":"Nigeria Centre for Disease Control (2018). Weekly Epidemiological Report, Week 52."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ingelbeen, B., Weregemere, N.A., Noel, H., Tshapenda, G.P., Mossoko, M., Nsio, J., Ronsse, A., Ahuka-Mundeke, S., Cohuet, S., and Kebela, B.I. (2018). Urban yellow fever outbreak-Democratic Republic of the Congo, 2016: Towards more rapid case detection. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0007029"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/0049475517699726","article-title":"Yellow fever from Angola and Congo: A storm gathers","volume":"47","author":"Ahmed","year":"2017","journal-title":"Trop. Doct."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3201\/eid2207.160469","article-title":"Yellow Fever in a Worker. Returning to China from Angola, March 2016","volume":"22","author":"Ling","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijid.2017.05.001","article-title":"Detection of yellow fever virus genomes from four imported cases in China","volume":"60","author":"Cui","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_17","unstructured":"Pan American Health Organization\/World Health Organization (2019). Epidemiological Update: Yellow Fever. 6 March 2019, PAHO\/WHO."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Pinheiro, G.G., Rocha, M.N., de Oliveira, M.A., Moreira, L.A., and Andrade Filho, J.D. (2019). Detection of Yellow Fever Virus in Sylvatic Mosquitoes during Disease Outbreaks of 2017\u20132018 in Minas Gerais State, Brazil. Insects, 10.","DOI":"10.3390\/insects10050136"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M17-1949","article-title":"Epizootic Outbreak of Yellow Fever Virus and Risk for Human Disease in Salvador, Brazil","volume":"168","author":"Souza","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.26633\/RPSP.2019.29","article-title":"Yellow fever outbreak in a rural-urban mixed community of Espirito Santo, Brazil: Epidemiological aspects","volume":"43","author":"Moussallem","year":"2019","journal-title":"Revista Panamericana de Salud P\u00fablica"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gossner, C.M., Haussig, J.M., de Bellegarde de Saint Lary, C., Kaasik Aaslav, K., Schlagenhauf, P., and Sudre, B. (2018). Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, July 2017 to March 2018. Eurosurveillance, 23.","DOI":"10.2807\/1560-7917.ES.2018.23.11.18-00106"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3389\/fmicb.2019.01079","article-title":"Distinct YFV Lineages Co-circulated in the Central-Western and Southeastern Brazilian Regions from 2015 to 2018","volume":"10","author":"Delatorre","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biosystems.2011.07.004","article-title":"Why dengue and yellow fever coexist in some areas of the world and not in others?","volume":"106","author":"Amaku","year":"2011","journal-title":"Biosystems"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e180278","DOI":"10.1590\/0074-02760180278","article-title":"Yellow fever outbreak in Brazil: The puzzle of rapid viral spread and challenges for immunisation","volume":"113","author":"Possas","year":"2018","journal-title":"Mem\u00f3rias do Instituto Oswaldo Cruz"},{"key":"ref_25","first-page":"441","article-title":"Estimating the size of Aedes aegypti populations from dengue incidence data: Implications for the risk of yellow fever outbreaks","volume":"2","author":"Massad","year":"2017","journal-title":"Infect. Dis. Model."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Dorigatti, I., Hamlet, A., Aguas, R., Cattarino, L., Cori, A., Donnelly, C.A., Garske, T., Imai, N., and Ferguson, N.M. (2017). International risk of yellow fever spread from the ongoing outbreak in Brazil, December 2016 to May 2017. Eurosurveill, 22.","DOI":"10.2807\/1560-7917.ES.2017.22.28.30572"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.15585\/mmwr.mm6711e1","article-title":"Fatal Yellow Fever in Travelers to Brazil, 2018","volume":"67","author":"Hamer","year":"2018","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"343B","DOI":"10.2471\/BLT.17.205658","article-title":"International travel between global urban centres vulnerable to yellow fever transmission","volume":"96","author":"Brent","year":"2018","journal-title":"Bull. World Health Organ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1590\/S0034-89102010005000046","article-title":"Yellow fever in Brazil: Thoughts and hypotheses on the emergence in previously free areas","volume":"44","author":"Vasconcelos","year":"2010","journal-title":"Rev. Saude Publica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3201\/eid2312.170685","article-title":"Outbreak of Yellow Fever among Nonhuman Primates, Espirito Santo, Brazil, 2017","volume":"23","author":"Fernandes","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15585\/mmwr.mm6617e2","article-title":"Addressing a Yellow Fever Vaccine Shortage - United States, 2016\u20132017","volume":"66","author":"Gershman","year":"2017","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Roukens, A.H.E., and Visser, L.G. (2019). Fractional-dose yellow fever vaccination: An expert review. J. Travel Med., 26.","DOI":"10.1093\/jtm\/taz024"},{"key":"ref_33","unstructured":"World Health Organization (2017). Eliminate yellow fever epidemics (EYE): A global strategy, 2017\u20132026. Wkly. Epidemiol. Rec., 16, 193\u2013204."},{"key":"ref_34","unstructured":"World Health Organization (1992). Division of Epidemiological Surveillance and Health Situation Trend Assessment. Global Health Situation and Projections\u2014Estimates, WHO."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e1001638","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow Fever in Africa: Estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLoS Med."},{"key":"ref_36","unstructured":"PAHO-WHO Member States (2019, October 25). Member States Reports to Health Emergency Information & Risk Assessment Unit (HIM) PAHO Health Emergencies Department (PHE): PAHO\u2013WHO; 2019. Available online: http:\/\/ais.paho.org\/phip\/viz\/ed_yellowfever.asp."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4269\/ajtmh.2010.09-0782","article-title":"Incubation periods of Yellow fever virus","volume":"83","author":"Johansson","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/trstmh\/tru092","article-title":"The whole iceberg: Estimating the incidence of yellow fever virus infection from the number of severe cases","volume":"108","author":"Johansson","year":"2014","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(19)30125-2","article-title":"Predictors of mortality in patients with yellow fever: An observational cohort study","volume":"19","author":"Kallas","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trstmh.2006.04.001","article-title":"Clinical and epidemiological characteristics of yellow fever in Brazil: Analysis of reported cases 1998-2002","volume":"101","author":"Tuboi","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e190033","DOI":"10.1590\/0074-02760190033","article-title":"Lipase and factor V (but not viral load) are prognostic factors for the evolution of severe yellow fever cases","volume":"114","author":"Casadio","year":"2019","journal-title":"Mem\u00f3rias do Instituto Oswaldo Cruz"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Duarte-Neto, A.N., Cunha, M.D.P., Marcilio, I., Song, A.T.W., de Martino, R.B., Ho, Y.L., Pour, S.Z., Dolhnikoff, M., Saldiva, P.H.N., and Duarte, M.I.S. (2019). Yellow fever and orthotopic liver transplantation: New insights from the autopsy room for an old but re-emerging disease. Histopathology.","DOI":"10.1111\/his.13904"},{"key":"ref_43","unstructured":"Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2018). Yellow Fever Vaccines. Vaccines, Elsevier. [7th ed.]."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0035-9203(81)90335-7","article-title":"Indirect fluorescent antibody test for the diagnosis of yellow fever","volume":"75","author":"Monath","year":"1981","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1590\/s1678-9946201759002","article-title":"Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults","volume":"59","author":"Miyaji","year":"2017","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3201\/eid2508.181432","article-title":"17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil","volume":"25","author":"Antonelli","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.54.4.533","article-title":"The Use of Mice in Tests of Immunity against Yellow Fever","volume":"54","author":"Sawyer","year":"1931","journal-title":"J. Exp. Med."},{"key":"ref_48","first-page":"177","article-title":"Duration of immunity in human yellow fever as shown by protective power of serum","volume":"4","author":"Bauer","year":"1930","journal-title":"J. Prev. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e01253-14","DOI":"10.1128\/mBio.01253-14","article-title":"Human genetic variation and yellow fever mortality during 19th century U.S. epidemics","volume":"5","author":"Blake","year":"2014","journal-title":"mBio"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e190098","DOI":"10.1590\/0074-02760190098","article-title":"Previous dengue or Zika virus exposure can drive to infection enhancement or neutralisation of other flaviviruses","volume":"114","author":"Oliveira","year":"2019","journal-title":"Mem\u00f3rias do Instituto Oswaldo Cruz"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/0974-777X.56257","article-title":"Anamnestic immune response to dengue and decreased severity of yellow Fever","volume":"1","author":"Izurieta","year":"2009","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2007.10.009","article-title":"Treatment of yellow fever","volume":"78","author":"Monath","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ho, Y.L., Joelsons, D., Leite, G.F.C., Malbouisson, L.M.S., Song, A.T.W., Perondi, B., Andrade, L.C., Pinto, L.F., D\u2019Albuquerque, L.A.C., and Segurado, A.A.C. (2019). Severe yellow fever in Brazil: Clinical characteristics and management. J. Travel Med., 26.","DOI":"10.1093\/jtm\/taz040"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zandi, K., Amblard, F., Amichai, S., Bassit, L., Tao, S., Jiang, Y., Zhou, L., Ollinger Russell, O., Mengshetti, S., and Schinazi, R.F. (2019). Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00889-19"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10774","DOI":"10.1128\/JVI.01253-16","article-title":"A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein","volume":"90","author":"Guo","year":"2016","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.antiviral.2013.01.011","article-title":"3\u2032,5\u2032Di-O-trityluridine inhibits in vitro flavivirus replication","volume":"98","author":"Selisko","year":"2013","journal-title":"Antivir. Res"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"de Freitas, C.S., Higa, L.M., Sacramento, C.Q., Ferreira, A.C., Reis, P.A., Delvecchio, R., Monteiro, F.L., Barbosa-Lima, G., James Westgarth, H., and Vieira, Y.R. (2019). Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007072"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","unstructured":"ClinicalTrials.gov (2019, October 25). A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03891420."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Deng, Y.Q., Dai, J.X., Ji, G.H., Jiang, T., Wang, H.J., Yang, H.O., Tan, W.L., Liu, R., Yu, M., and Ge, B.X. (2011). A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016059"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13975","DOI":"10.1128\/JVI.78.24.13975-13986.2004","article-title":"Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes","volume":"78","author":"Crill","year":"2004","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1128\/JVI.00080-06","article-title":"Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites","volume":"80","author":"Stiasny","year":"2006","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"12919","DOI":"10.1128\/JVI.78.23.12919-12928.2004","article-title":"Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein","volume":"78","author":"Goncalvez","year":"2004","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/599794","article-title":"Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus","volume":"200","author":"Zhang","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1073\/pnas.1815432116","article-title":"Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope","volume":"116","author":"Long","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","unstructured":"ClinicalTrials.gov (2019, October 25). Safety and Tolerability of an Antibody against Yellow Fever Virus (TY014) in Humans, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03776786."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1038\/s41598-018-26800-y","article-title":"Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513","volume":"8","author":"Wong","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Brunette, G.W., and Nemhauser, J.B. (2019). Travel-Related Infectious Diseases. Yellow Fever. CDC Yellow Book 2020 Health Information for International Travel, Oxford University Press.","DOI":"10.1093\/med\/9780190928933.003.0004"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s13071-018-3063-6","article-title":"Spatio-temporal spillover risk of yellow fever in Brazil","volume":"11","author":"Kaul","year":"2018","journal-title":"Parasites Vectors"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1590\/S0036-46652013000100008","article-title":"Yellow fever epizootics in non-human primates, Sao Paulo state, Brazil, 2008-2009","volume":"55","author":"Moreno","year":"2013","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Bowman, L.R., Donegan, S., and McCall, P.J. (2016). Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004551"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pt.2015.04.015","article-title":"Evidence-based vector control? Improving the quality of vector control trials","volume":"31","author":"Wilson","year":"2015","journal-title":"Trends Parasitol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Yakob, L., Funk, S., Camacho, A., Brady, O., and Edmunds, W.J. (2017). Aedes aegypti Control Through Modernized, Integrated Vector Management. PLoS Curr., 9.","DOI":"10.1371\/currents.outbreaks.45deb8e03a438c4d088afb4fafae8747"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Roiz, D., Wilson, A.L., Scott, T.W., Fonseca, D.M., Jourdain, F., Muller, P., Velayudhan, R., and Corbel, V. (2018). Integrated Aedes management for the control of Aedes-borne diseases. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006845"},{"key":"ref_76","first-page":"647","article-title":"Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2214-109X(18)30024-X","article-title":"Existing and potential infection risk zones of yellow fever worldwide: A modelling analysis","volume":"6","author":"Shearer","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.01.074","article-title":"POLICI: A web application for visualising and extracting yellow fever vaccination coverage in Africa","volume":"37","author":"Hamlet","year":"2019","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Polonsky, J.A., Baidjoe, A., Kamvar, Z.N., Cori, A., Durski, K., Edmunds, W.J., Eggo, R.M., Funk, S., Kaiser, L., and Keating, P. (2019). Outbreak analytics: A developing data science for informing the response to emerging pathogens. Philos. Trans. R. Soc. B, 374.","DOI":"10.1098\/rstb.2018.0276"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kraemer, M.U.G., Cummings, D.A.T., Funk, S., Reiner, R.C., Faria, N.R., Pybus, O.G., and Cauchemez, S. (2019). Reconstruction and prediction of viral disease epidemics. Epidemiol. Infect., 147.","DOI":"10.1017\/S0950268818002881"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"20180335","DOI":"10.1098\/rstb.2018.0335","article-title":"Mosquito and primate ecology predict human risk of yellow fever virus spillover in Brazil","volume":"374","author":"Childs","year":"2019","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1084\/jem.65.6.801","article-title":"The Adaptation of Unmodified Strains of Yellow Fever Virus to Cultivation in Vitro","volume":"65","author":"Smith","year":"1937","journal-title":"J. Exp. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4269\/ajtmh.1928.s1-8.103","article-title":"Experimental transmission of yellow fever to laboratory animals","volume":"8","author":"Stokes","year":"1928","journal-title":"Am. J. Trop. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.65.6.767","article-title":"The Effect of Prolonged Cultivation in Vitro Upon the Pathogenicity of Yellow Fever Virus","volume":"65","author":"Theiler","year":"1937","journal-title":"J. Exp. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1016\/j.vaccine.2010.10.070","article-title":"WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13\u201314 May 2009","volume":"28","author":"Ferguson","year":"2010","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMp1606997","article-title":"Yellow Fever in Angola and Beyond\u2014The Problem of Vaccine Supply and Demand","volume":"375","author":"Barrett","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S1473-3099(17)30419-X","article-title":"Global yellow fever vaccination coverage from 1970 to 2016: An adjusted retrospective analysis","volume":"17","author":"Shearer","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"780","DOI":"10.15585\/mmwr.mm6629a4","article-title":"Update: Temporary Total Depletion of U.S. Licensed Yellow Fever Vaccine for Civilian Travelers Addressed by Investigational New Drug Use of Imported Stamaril Vaccine","volume":"66","author":"Gershman","year":"2017","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/S0140-6736(16)31838-4","article-title":"Fractional dosing of yellow fever vaccine to extend supply: A modelling study","volume":"388","author":"Wu","year":"2016","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"World Health Organization (2017). WHO position on the use of fractional doses\u2014June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper\u2014June 2013. Vaccine, 35, 5751\u20135752.","DOI":"10.1016\/j.vaccine.2017.06.087"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2017.14258","article-title":"Vaccination Challenges in Confronting the Resurgent Threat From Yellow Fever","volume":"318","author":"Chen","year":"2017","journal-title":"J. Am. Med Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3389\/fimmu.2019.01211","article-title":"Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine","volume":"10","author":"Fradico","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJMoa1710430","article-title":"Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak\u2014Final Report","volume":"381","author":"Casey","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Lindsey, N.P., Rabe, I.B., Miller, E.R., Fischer, M., and Staples, J.E. (2016). Adverse event reports following yellow fever vaccination, 2007\u20132013. J. Travel Med., 23.","DOI":"10.1093\/jtm\/taw045"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.1016\/j.vaccine.2010.10.015","article-title":"Is it time for a new yellow fever vaccine?","volume":"28","author":"Hayes","year":"2010","journal-title":"Vaccine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","article-title":"Questions regarding the safety and duration of immunity following live yellow fever vaccination","volume":"15","author":"Amanna","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_99","unstructured":"Centers for Disease Control and Prevention (2019, October 25). Contraindications for Administering Yellow Fever Vaccine, Available online: https:\/\/www.cdc.gov\/travel-training\/local\/HistoryEpidemiologyandVaccination\/contraindications-administering-yellow-fever-vaccine.pdf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","article-title":"Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"30","author":"Gershman","year":"2012","journal-title":"Vaccine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20182295","article-title":"Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines","volume":"216","author":"Hernandez","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_102","first-page":"279","article-title":"Notes from the field: Fatal yellow fever vaccine-associated viscerotropic disease\u2014Oregon, September 2014","volume":"64","author":"DeSilva","year":"2015","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.trstmh.2007.06.013","article-title":"Acute viscerotropic disease following vaccination against yellow fever","volume":"101","author":"Hayes","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Roukens, A.H., Soonawala, D., Joosten, S.A., de Visser, A.W., Jiang, X., Dirksen, K., de Gruijter, M., van Dissel, J.T., Bredenbeek, P.J., and Visser, L.G. (2011). Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: A prospective controlled cohort study. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027753"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Meier, K.C., Gardner, C.L., Khoretonenko, M.V., Klimstra, W.B., and Ryman, K.D. (2009). A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000614"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"12392","DOI":"10.1128\/JVI.02149-13","article-title":"Dynamic viral dissemination in mice infected with yellow fever virus strain 17D","volume":"87","author":"Erickson","year":"2013","journal-title":"J. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9951","DOI":"10.1038\/s41598-019-46389-0","article-title":"Human Schwann cells are susceptible to infection with Zika and yellow fever viruses, but not dengue virus","volume":"9","author":"Dhiman","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_109","unstructured":"Stuart, G. (1956). Rections Folowing Vaccination against Yellow Fever, World Health Organization."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/08998280.2019.1573405","article-title":"Transverse myelitis associated with yellow fever vaccination","volume":"32","author":"Bartol","year":"2019","journal-title":"Bayl. Univ. Med Cent. Proc."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Goldstein, E.J., Bell, D.J., and Gunson, R.N. (2019). Yellow fever vaccine-associated neurological disease: It is not just the silver generation at risk. BMJ Case Rep., 12.","DOI":"10.1136\/bcr-2019-229558"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.vaccine.2006.11.027","article-title":"Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases","volume":"25","author":"McMahon","year":"2007","journal-title":"Vaccine"},{"key":"ref_113","first-page":"269","article-title":"Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk","volume":"87","author":"Traiber","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1503\/cmaj.100619","article-title":"Case report: Probable transmission of vaccine strain of yellow fever virus to an infant via breast milk","volume":"183","author":"Kuhn","year":"2011","journal-title":"CMAJ"},{"key":"ref_115","unstructured":"Centers for Disease Control and Prevention (2010). Transmission of yellow fever vaccine virus through breast-feeding-Brazil, 2009. Morb. Mortal. Wkly. Rep., 59, 130\u2013132."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J. Clin. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_118","unstructured":"World Health Organization (2013). Background Paper on Yellow Fever Vaccine, World Health Organization. SAGE Working Group."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3389\/fimmu.2019.02192","article-title":"Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children","volume":"10","author":"Reis","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1016\/j.vaccine.2019.04.077","article-title":"Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture","volume":"37","author":"Pato","year":"2019","journal-title":"Vaccine"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Roukens, A.H., Vossen, A.C., Bredenbeek, P.J., van Dissel, J.T., and Visser, L.G. (2008). Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: A randomized controlled non-inferiority trial. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0001993"},{"key":"ref_122","first-page":"159","article-title":"Intradermal vaccination to protect against yellow fever and influenza","volume":"351","author":"Roukens","year":"2012","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Watson, A.M., Lam, L.K., Klimstra, W.B., and Ryman, K.D. (2016). The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005786"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Perdomo-Celis, F., Salvato, M.S., Medina-Moreno, S., and Zapata, J.C. (2019). T-Cell Response to Viral Hemorrhagic Fevers. Vaccines, 7.","DOI":"10.3390\/vaccines7010011"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.1016\/j.vaccine.2009.06.023","article-title":"Production of yellow fever virus in microcarrier-based Vero cell cultures","volume":"27","author":"Souza","year":"2009","journal-title":"Vaccine"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jviromet.2008.03.002","article-title":"Pressure-inactivated yellow fever 17DD virus: Implications for vaccine development","volume":"150","author":"Gaspar","year":"2008","journal-title":"J. Virol. Methods"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1016\/j.vaccine.2015.03.077","article-title":"An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures","volume":"33","author":"Pereira","year":"2015","journal-title":"Vaccine"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virusres.2013.04.003","article-title":"Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes","volume":"176","author":"Beasley","year":"2013","journal-title":"Virus Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide-based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3389\/fimmu.2018.01756","article-title":"Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model","volume":"9","author":"Julander","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_133","unstructured":"ClinicalTrials.gov (2019, October 25). A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine with and without Montanide ISA-720 Adjuvant in 18\u201345 Year Old Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02743455?type=Intr&cond=yellow+fever&phase=0&fund=0&rank=1."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/4\/179\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:32:50Z","timestamp":1760189570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/4\/179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":133,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["vaccines7040179"],"URL":"https:\/\/doi.org\/10.3390\/vaccines7040179","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]}}}